TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

OVERVIEW OF ACTIVITY
Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 171,550 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2016 and 58,320 individuals will die from these diseases. Of note, more than 60 drug products are currently labeled for use in the management of hematologic cancers with more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphoma, including CLL, where substantial progress has been made over the past several years in the development and evaluation of novel agents. Mature clinical trial results have illustrated the efficacy of several new investigational therapies, a number of which have now entered the clinic. Furthermore, enthusiasm is widespread that additional important advancements are on the horizon as other novel agents and strategies have already been associated with impressive clinical benefit.

This dynamic therapeutic environment clearly highlights the need for all members of the oncology/hematology care team to remain abreast of the ongoing sea change in the management of these diseases, particularly oncology nurses, who play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the sixth part of an 8-part integrated CNE curriculum originally held at the 2016 ONS Annual Congress feature discussions with leading oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lymphomas and CLL.

LEARNING OBJECTIVES
• Provide patient-focused education to enhance clinical decision-making regarding the available systemic agents used in the management of indolent and aggressive forms of B-cell NHL, T-cell lymphomas and HL.
• Formulate supportive care strategies to manage the side effects associated with commonly employed therapeutic interventions for patients with HL, NHL and CLL.
• Appreciate the FDA approvals of the novel targeted agents ibrutinib, idelalisib and obinutuzumab for the treatment of newly diagnosed and relapsed/refractory (R/R) CLL, and discern how these therapies can be safely integrated into routine clinical practice.
• Recall available safety and efficacy data with bortezomib, lenalidomide and ibrutinib, and use this information when discussing recommendations regarding the selection and sequencing of therapy for R/R mantle-cell lymphoma.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENTS
This educational activity for 2.1 contact hours is provided by Research To Practice during the period of August 2016 through August 2017.
This activity is awarded 2.1 ANCC pharmacotherapeutic contact hours.
ONC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/ONS2016/ILNA.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

FOR SUCCESSFUL COMPLETION
This is a video CNE program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSLymphoma2016/CNE.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Michelle A Fanale, MD
Associate Professor
Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: Merck, Spectrum Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc; Honoraria: Merck, Spectrum Pharmaceuticals Inc, Seattle Genetics, Takeda Oncology.

Amy Goodrich, CRNP-AC
Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

No relevant conflicts of interest to disclose.

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York


Katey Stephens, MS, ANP
Nurse Practitioner
Division of Hematologic Malignancies
Lymphoma and Stem Cell Malignancies
Dana-Farber Cancer Institute
Boston, Massachusetts

No relevant conflicts of interest to disclose.


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company and Seattle Genetics.

**Hardware/Software Requirements:**
- A high-speed Internet connection
- A monitor set to 1280 x 1024 pixels or more
- Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
- Adobe Flash Player 10.2 plug-in or later
- Adobe Acrobat Reader
- (Optional) Sound card and speakers for audio

**Last review date:** August 2016  
**Expiration date:** August 2017  
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.


Chen RW et al. Results of a phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory HL prior to AHCT. *Proc ASH* 2014;Abstract 501.


Le Gouill S et al. Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: First interim analysis of the phase III prospective LyMa trial, a LYSA study. *Proc ASH* 2014;Abstract 146.


Moskowitz CH et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study. *Proc ASH* 2014;Abstract 290.


Select Publications


Wang ML et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: Preliminary results from a phase II clinical trial. *Proc ASH* 2014;Abstract 627.


Woyach JA et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. *Blood* 2012;120(6):1175-84.